Table 1 Patients' baseline characteristics by treatment group at study entry (visit 2)
Placebo | Formoterol 4.5 μg | Formoterol 9 μg | |
|---|---|---|---|
N | 208 | 206 | 199 |
Mean age, years (range) | 66.3 (40-86) | 66.7 (41-85) | 67.2 (44-88) |
Patients ≥ 65 years, % | 59.6% | 64.6% | 60.8% |
Male, % | 89.4% | 88.8% | 85.4% |
Japanese/European, n (%) | 110/98 (52.9%/47.1%) | 106/100 (51.5%/48.5%) | 108/91 (54.3%/45.7%) |
Mean smoking pack years (range) | 47.4 (10-152) | 46.1 (10-150) | 46.5 (11-175) |
Mean duration of disease, years (range) | 4.3 (0-25) | 4.2 (0-39) | 4.9 (0-34) |
Mean FEV1, L (range)a | 1.37 (0.48-3.17) | 1.30 (0.48-3.10) | 1.30 (0.25-2.72) |
Mean FEV1, % of predicted normal (range)a | |||
52.5 (16.6-83.7) | 50.4 (22.0-79.4) | 51.5 (9.3-79.5) | |
Patients with FEV1 ≤ 50%, % | 43.3% | 50.5% | 48.2% |
Mean FEV1/FVC ratio, % (range)a | 45.6 (20.5-68.8) | 44.6 (23.0-70.4) | 46.5 (18.1-77.2) |
Mean FEV1 reversibility, % (range) | 11.3 (-30.3-67.2) | 10.5 (-17.9-61.6) | 10.7 (-57.4-63.6) |